期權大單 | 一篇論文引發股價拉昇！輝瑞期權成交量激增，Call佔比逾八成
一、市場概覽 （5月22日）
在債務上限談判的陰影下，週一美股市場整體在觀望中維持震盪，科技股的表現略好於大盤。截至收盤，標普500漲0.02%，報4192.63點；納斯達克指數漲0.5%，報12720.78點；道瓊斯工業指數跌0.42%，報33286.58點。
期權市場總成交量3400.21萬張合約，環比前一交易日（4280.78萬張合約）大幅減少，且低於90日平均成交量（4043.2萬張合約），其中看漲期權佔比55%。
二、期權成交總量TOP10
標普指數ETF期權成交744萬張合約，其中看漲期權佔比43.2%；納指100ETF期權成交238.1萬張合約，其中看漲期權佔比38.7%。
美股大型科技股隔夜漲跌不一，特斯拉漲近5%，谷歌A漲近2%，亞馬遜跌超1%，蘋果跌0.55%；期權成交量環比前一交易日均有所下滑，其中特斯拉成交216萬張合約、亞馬遜成交61.37萬張合約、蘋果成交59.37萬張合約、谷歌A成交49.53萬張合約；
三、異動觀察
數據來源：Market Chameleon
輝瑞隔夜收漲逾5%，期權成交46.62萬張合約，較90日平均成交量放大逾5倍，看漲期權佔比82.2%；其中2023年6月16日到期的40美元行使價看漲期權的成交量較高，成交2.99萬張；消息面，研究結果顯示：輝瑞製藥口服減肥藥可能是有效的，其作用可能比Novo Nordisk的注射劑Ozempic更快；
數據來源：Market Chameleon
Upstart Holdings隔夜大幅收漲近20%，期權成交37.3萬張合約，較90日平均成交量放大逾4倍，看漲期權佔比65.9%；其中2023年5月26日到期的30美元行使價看漲期權的成交量較高，成交2.29萬張；
數據來源：Market Chameleon
美光科技隔夜收跌近3%，期權成交22.47萬張合約，較90日平均成交量放大逾2倍，看跌期權佔比58.5%；其中2023年5月26日到期的65美元行使價看跌期權的成交量較高，成交2.7萬張；消息面，該公司在華銷售產品未通過網絡安全審查；
數據來源：Market Chameleon
Zoom發佈最新業績，盤後股價一度漲至6%，隨後收窄至1%；期權成交16.35萬張合約，較90日平均成交量放大近5倍，看漲期權佔比47.8%；其中2023年6月16日到期的85美元行使價看漲期權的成交量較高，成交1.35萬張；消息面，該公司一季度營收同比增3%至11.1億美元，上調全年指引。
數據來源：Market Chameleon
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
